Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells

Shu Wang1,2, Lei Wang2,3, Zhiyang Zhou2,4, Qipan Deng2, Ling Li4, Mingzhi Zhang4, Linlin Liu1 & Yong Li2

Colorectal cancer is a major cancer type worldwide. 5-fluorouracil, often given with leucovorin, is the most commonly used drug in colorectal cancer chemotherapy, yet development of drug resistance to 5-fluorouracil in colorectal cancer cells is the primary cause of chemotherapy failure. Most patients receiving intravenous 5-fluorouracil develop side effects. Leucovorin, due to its vitamin-like profile, has few side-effects. Drug repurposing is the application of approved drugs to treat new indications. In this study, we performed a novel drug-repurposing screening to identify Food and Drug Administration-approved chemotherapeutic compounds possessing synergistic activity with leucovorin against colorectal cancer cells. We found that the combination of bortezomib and leucovorin enhanced caspase activation and increased apoptosis in colorectal cancer cells better than either agent alone. Further, the synergistic induction of apoptosis and inhibition of tumor growth were also observed in mouse colorectal cancer xenografts. These data support leucovorin enhances the anti-cancer effect of bortezomib and present this novel combinatorial treatment against colorectal cancer.

Colorectal cancer (CRC) is the third most common malignant tumor and the fourth most common cause of cancer deaths worldwide1. CRC is treated through surgery combined with radiation and/or chemotherapy, depending on the tumor site and disease stage2,3. The standard cytotoxic chemotherapy regimens for CRC patients are FOLFOX containing leucovorin calcium (also known as folinic acid, FOL), 5-fluorouracil (5-FU), and oxaliplatin and FOLFIRI containing FOL, 5-FU, and irinotecan hydrochloride, FOLFIRI4–6. Despite an initial clinical response rate of 40–50% is achieved, a large portion of CRC tumors eventually develop resistance to 5-FU7,8. Therefore, there is an unmet clinical need for novel therapeutic agents or new combination treatments to achieve CRC remission.

Leucovorin itself has no intrinsic cytotoxic activity. Leucovorin is a 5-formyl derivative of tetrahydrofolic acid that is converted to other reduced folic acid derivatives (e.g., tetrahydrofolate) and thus has vitamin activity equivalent to that of folic acid. Leucovorin enhances 5-FU antitumor activity by inhibiting thymidylate synthase in tumor cells9,10. 5-FU incurs common adverse effects, including inflammation of the mouth, loss of appetite, low blood cell counts, hair loss, and inflammation of the skin. On the other hand, due to its vitamin-like properties, leucovorin is generally considered safe and has fewer side effects than 5-FU, oxaliplatin, and other cytotoxic agents used in CRC chemotherapeutic regimens. We hypothesize that beyond 5-FU, leucovorin has synergistic anti-cancer activity against CRC with other chemotherapeutic agents. In this study, we performed a small-scale drug screening to identify Food and Drug Administration (FDA)-approved oncologic drugs that in combination with leucovorin inhibit CRC cell growth and tumorigenesis. We found that the combination of bortezomib and leucovorin is superior to either agent alone in elevating CRC apoptosis and attenuating tumor growth. These data support a new regimen to treat this deadly malignancy.

Received: 14 February 2017
Accepted: 15 March 2017
Published online: 06 April 2017

1Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, Jilin Province, 130041, China.
2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
3Key Laboratory of Ecology and Environmental Science in Guangdong Higher Education, Guangdong Provincial Key Laboratory for Healthy and Safe Aquaculture, College of Life Science, South China Normal University, Guangzhou, 510631, China.
4Department of Oncology, The First Affiliated Hospital of Zhengzhou University; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan Province, 450000, China. Correspondence and requests for materials should be addressed to L.L. (email: 2660424632@qq.com) or Y.L. (email: liy2@ccf.org)
Results

Bortezomib and leucovorin synergistically inhibited the viability of CRC cells. First, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, we screened FDA-approved anti-cancer drugs set, which contained 119 compounds (https://dtp.cancer.gov/). These compounds were obtained from the Approved Oncology Drugs Set VI at the NCI Developmental Therapeutics Program and were used with a final concentration of 0.5 μM with or without leucovorin (10 μM) to treat human CRC HCT116 cells (Fig. 1A). When combined with leucovorin, 13 compounds had at least a 25% increase in anti-CRC activity, as measured by the MTT assay, compared to these agents alone (Fig. 1B). We then performed time-course and dose-response studies of leucovorin in combination with each of the selected 13 compounds in HCT116 and HT29 CRC cells and assessed viability using the CellTiter-Glo assay. Only the combination of leucovorin and bortezomib decreased cell viability by more than 25% for both cell lines compared with each compound alone (Fig. 1C,D). The combination of leucovorin and any of the 12 other compounds did not inhibit HT29 cell viability with the 25% improvement. In particular, combinatorial treatment with bortezomib and leucovorin caused synergistic cell death compared with single-drug treatment at 48 h (HCT116, p < 0.01 and HT29,
p < 0.05). Combination index (CI) values for each fraction affected were calculated by median drug effect analysis according to the method of Chou and Talalay. In this method, CI < 1.0 indicates synergy; CI = 1.0 indicates an additive effect; and CI > 1.0 indicates antagonism. We found the CI values ranged from 0.50 to 0.85 with leucovorin (10 μM) and three concentrations of bortezomib (3, 10, 30 nM) for both cell lines (Table 1), supporting that the combination of bortezomib and leucovorin exerts a synergistic effect.

### Table 1. Combination index (CI) values for the combination of bortezomib and leucovorin for HCT116 and HT29 cells.

| Bortezomib dose (nM) | Leucovorin dose (μM) | Combination index (CI)* |
|----------------------|----------------------|-------------------------|
|                      |                      | HCT116                  | HT29                  |
| 3                    | 10                   | 0.50                    | 0.65                  |
| 10                   | 10                   | 0.42                    | 0.48                  |
| 30                   | 10                   | 0.85                    | 0.81                  |

Bortezomib and leucovorin induced apoptosis in CRC cells. We investigated whether the synergistic killing of CRC cells by bortezomib and leucovorin was due to apoptosis. HCT116 and HT29 cells were treated with bortezomib (3 nM or 10 nM), leucovorin (10 μM), or the combination for 12 and 24 h. The treated cells were stained with FITC-annexin V/propidium iodide, and apoptosis was analyzed with flow cytometry. Experiments were performed three times with one representative experiment shown. Cells that underwent late apoptotic death and early apoptotic death are in the upper and lower right quadrants, respectively. (B, D). Percent apoptotic cells. One-way ANOVA was performed to compare each treatment group with the vehicle control (PBS) or to compare the combination with bortezomib alone. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

**Bortezomib and leucovorin induced apoptosis in CRC cells.** We investigated whether the synergistic killing of CRC cells by bortezomib and leucovorin was due to apoptosis. HCT116 and HT29 cells were treated with bortezomib (3 nM or 10 nM), leucovorin (10 μM), or the combination for 12 and 24 h. The treated cells were assayed for apoptosis using annexin V/propidium iodide (PI) staining followed by flow cytometry. Bortezomib plus leucovorin treatment resulted in a higher percentage of apoptotic cells, when compared with either drug alone, in a time- and dose-dependent manner (Fig. 2A, C). Flow cytometry data clearly showed a synergistic induction of apoptosis with the combined treatment. At 24 h, the percentage of apoptotic cells upon treatment with the combination of bortezomib (10 nM) and leucovorin (10 μM) or bortezomib (10 nM) alone increased 15% in HCT116 and 18% in HT29, respectively (Fig. 2B, D). These results suggest that apoptosis induction contributes to the synergistic killing of CRC cells by bortezomib and leucovorin.
Bortezomib and leucovorin induced G2/M arrest of CRC cells. It is reported that bortezomib induces G2/M arrest in human colon cancer cells\textsuperscript{12}. To monitor cell cycle, HCT116 and HT29 cells were treated with bortezomib (10 nM) with or without leucovorin (10 μM) for 24 h and subjected to flow cytometry. Cell cycle distribution analysis was performed using FlowJo. (B,C) Histogram showing the percentage of HCT116 and HT29 cells in the sub-G1, G0-G1, S, and G2/M phases. (D) Representative cell cycle histogram demonstrating the percentage of cells in the G2/M phase. *P ≤ 0.05. **P ≤ Each experiment was performed four times, and values are presented as the mean ± SE.

Figure 3. The combination of bortezomib and leucovorin induced G2/M arrest in CRC cells. (A) Colon cancer cells were treated with 10 nM bortezomib and/or 10μM leucovorin or appropriate concentration of vehicle control for 24 h. The cells were harvested, washed with PBS, typsinized, fixed overnight with 70% ethanol at −20°C, and stained with PI solution before being subjected to flow cytometry. Cell cycle distribution analysis was performed using FlowJo. (B,C) Histogram showing the percentage of HCT116 and HT29 cells in the sub-G1, G0-G1, S, and G2/M phases. (D) Representative cell cycle histogram demonstrating the percentage of cells in the G2/M phase. *P ≤ 0.05. **P ≤ Each experiment was performed four times, and values are presented as the mean ± SE.

Bortezomib and leucovorin induced G2/M arrest of CRC cells. It is reported that bortezomib induces G2/M arrest in human colon cancer cells\textsuperscript{12}. To monitor cell cycle, HCT116 and HT29 cells were treated with bortezomib (10 nM) with or without leucovorin (10 μM) for 24 h and subjected to flow cytometry (Fig. 3A). We analyzed the cell cycle distribution for both cell lines using FlowJo (Fig. 3B,C). An increase in the percentage of cells in G2/M phase was observed in both cell lines when treated with bortezomib; adding leucovorin further increased the percentage in G2/M phase (Fig. 3D). These data indicate that leucovorin enhances bortezomib-mediated cell cycle arrest of CRC cells.

Synergistic induction of apoptosis by bortezomib and leucovorin is mediated through an increase in caspase activation. As the combination treatment enhanced apoptosis, we next examined whether this increased apoptosis is mediated by caspase activation. Using western blotting, we analyzed the proteolytic cleavage of poly (ADP-ribose) polymerase (PARP), caspase-3, -8, -9, and the expression of BCL-2 in both HCT116 and HT29 cells. In HCT116 cells treated with a low dose of bortezomib alone (3 nM), cleavage of PARP, but not the caspases, was detected (Fig. 4A). Adding leucovorin (10 μM) to bortezomib (3 nM) led to cleavage of caspase 8 and 9. With high-dose bortezomib (10 nM) alone, the processing of PARP and caspases -3, -8, and - 9 was readily detectable in HCT116 cells, whereas the combination strongly enhanced caspase-3 processing. BCL-2, a negative regulator of apoptosis, was downregulated in HCT116 cells receiving low- or high-dose bortezomib, but leucovorin did not enhance the downregulation. Similar results were obtained for cleavage of PARP and the caspases in HT29 cells (Fig. 4B). In addition, in HT29 cells BCL-2 downregulation was only observed with high-dose bortezomib (10 nM) plus leucovorin, unlike in HCT116 cells. Overall, these results indicate that leucovorin augments the cleavage of PARP and caspases in bortezomib-induced CRC cell apoptosis.

Bortezomib and leucovorin induced the activation of DNA damage signaling pathway. It is reported that proteasome inhibitors induce p53-dependent apoptosis in cancer cells\textsuperscript{13}. Therefore, we investigated the DNA damage response in HCT116 and HT29 cells by western blotting. In HCT116 cells (which retain a wild-type TP53 gene)\textsuperscript{14}, phosphorylation of p53 at Ser-46 was elevated with bortezomib (10 nM) treatment, while the addition of leucovorin (10 μM) further increased the level of phospho-p53 (Fig. 4C). Next we determined the
expression of the p53 transactivational targets, Puma, Bax, and p21, in HCT116 cells and found their expression followed a similar pattern (Fig. 4D).

Phosphorylation of H2AX, a marker of DNA damage and repair, is an early cellular response to the induction of DNA double-strand breaks. This phosphorylation event has emerged as a highly specific and sensitive molecular marker for monitoring DNA damage initiation and resolution15. We monitored the expression and phosphorylation of H2AX in HCT116 cells and detected a low level of phospho-H2AX with bortezomib treatment. However, the combination treatment markedly increased H2AX phosphorylation compared with bortezomib alone (Fig. 4C). Beyond CRC cells, bortezomib treatment induces H2AX phosphorylation in gastrointestinal stromal tumor cells and esophageal squamous cell carcinoma cells16, 17. However, the exact mechanism underlying such induction is unknown. Increased phosphorylation of Bcl-xL at Ser-62 was observed with combination treatment in both HCT116 and HT29 cells (Fig. 4C,D).

We also determined the expression of p53 and its transactivational targets in HT29 cells. As the p53 gene in HT29 cells is mutated18, p53 is neither upregulated nor phosphorylated (Fig. 4D). Yet we found that bortezomib

Figure 4. Bortezomib and leucovorin induce activation of caspases and the DNA damage response. HCT116 (A,C,E) and HT29 (B,D,F) cells were treated with bortezomib (3 or 10 nM) and 10 μM leucovorin or with a single agent for 24 h. Cell lysates were separated by SDS-PAGE and the target protein expression was analyzed by western blotting analysis. Actin was used as a loading control. (A,B) PARP and caspases, (C,D) p53 and its targets, (E,F) kinase signaling.
treatment upregulated expression of all three p53 transactivational targets and the upregulation was further enhanced by leucovorin. In addition, bortezomib treatment increased H2AX phosphorylation, which was further augmented by leucovorin in HT29 cells. These results suggest that upregulation of PUMA, Bax, p21, and H2AX phosphorylation may not be dependent on a functional p53 gene, at least in HT29 cells. Taken together, these data imply that cell death induced by bortezomib and leucovorin depends on the activation of pro-apoptotic factors such as PUMA and Bax, anti-apoptotic factors as phosphorylated Bcl-xl, and increased DNA damage response as judged by H2AX phosphorylation

Bortezomib and leucovorin induced the activation of other pathways. Previous studies indicate that mitogen-activated protein kinase (MAPK) pathways play a critical role in the development and progression of cancer. The extracellular signal-regulated kinases (ERKs) and c-Jun N-terminal kinases (JNKs) are two major MAPK classes. ERK is a downstream component of an evolutionarily conserved signaling module, and its activation also promotes an autocrine growth loop critical for tumor growth. JNK activity is tumor suppressive and JNK inhibitors have been considered for cancer therapy due to their ability to promote apoptosis. Western blotting analysis indicated that in HCT116 and HT29 cells, bortezomib alone and to a markedly greater extent combination treatment, inhibited phospho-ERK1/2 expression but activated JNK (Fig. 4E,F). Akt (protein kinase B), is a serine/threonine-specific protein kinase and activated by phosphorylation at Ser-473 that promotes cell growth and confers resistance to apoptosis. We found that Akt phosphorylation was down-regulated in the combinatorial treatment compared with either agent alone (Fig. 4E,F). These results suggest that bortezomib and leucovorin activate JNK signaling, but inhibit the activation of ERK and Akt, suggesting that this combination has multifaceted actions against CRC.

Bortezomib and leucovorin attenuate HCT116 xenograft tumorigenesis. Finally, we evaluated the in vivo anti-tumor effect of bortezomib and leucovorin on CRC xenografts. HCT116 cells were inoculated subcutaneously on the right flank of immunodeficient NOD scid gamma (NSG) mice. Once tumors were established (tumor volume reached ~200 mm³), mice (n = 5 each group) were injected intraperitoneally with the vehicle control (phosphate-buffered saline, PBS), 0.5 mg/kg bortezomib, 80 mg/kg leucovorin, or the combination twice per week. Tumor size and mouse body weight were measured during the treatment. There were no significant differences in animal body weight throughout the study. We found that leucovorin treatment had no effect on tumor growth, but bortezomib treatment suppressed tumor growth significantly (Fig. 5A,B). Moreover, the combination of bortezomib and leucovorin inhibited tumorigenesis to a greater extent than bortezomib alone. Western blotting analyses demonstrated that enhanced cleavage of PARP and caspases (-3, -8, and -9) and activated the expression of PUMA and p21 in tumors resected from NSG mice treated with both agents compared to either agent alone (Fig. 5D). The terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay confirmed more apoptotic cell death in xenograft tumor tissues at day 16 after bortezomib and leucovorin combination treatment in comparison to either agent alone or the vehicle control (Fig. 5E,F). These data suggest that bortezomib and leucovorin were able to induce apoptosis and attenuate tumor growth in vivo.

Discussion

Bortezomib (Velcade®, also known as PS-341) is the first proteasome inhibitor approved by the FDA for treating multiple myeloma. Ongoing experimental studies and clinical trials have revealed that, as a single agent or in combination with other conventional anti-cancer drugs, bortezomib has inhibitory effects on various types of solid tumors, such as colon and gastric cancers, and breast, prostate, and lung cancers. At present, bortezomib was approved by the FDA for the treatment of patients with multiple myeloma or patients with mantle cell lymphoma. Specific to CRC, we note that several cell culture-based studies demonstrate that bortezomib alone inhibits cell growth and xenograft tumorigenesis. Several clinical trials targeting CRC using bortezomib and/or other drugs have been performed or are ongoing (https://clinicaltrials.gov/). One of the questions concerning bortezomib use in CRC therapy is whether this protease inhibitor interferes with other chemotherapeutic agents widely used in today's standard regimens, specifically FOLFOX and FOLFIRI. Both regimens share two common components: 5-fluorouracil (a cytotoxic compound with significant side-effects) and leucovorin (a vitamin-like drug with a stellar safety profile). In this study, we performed a drug-repurposing screening to identify the potent cancer agents already approved by the FDA that reduce CRC cell proliferation in combination with leucovorin. We showed that combining bortezomib and leucovorin could potently induce the killing of CRC cells through a mechanism involving the summative effect of caspase-dependent apoptosis. In combination with leucovorin, bortezomib strongly induced the cleavage of PARP, caspase-3, -8 and -9, and down-regulated the anti-apoptosis factor BCL-2. These data indicate that apoptosis is a major downstream event of the two-drug combination that inhibits CRC cell growth and tumorigenesis in mice. This is likely to be accompanied by inhibition of cell cycle progression.

We also found that the combinatorial treatment inhibits the activation of ERK and Akt, two major cancer cell survival pathways, and promotes JNK activation. The phosphorylation of Bcl-xl, a downstream effector of JNK signaling, is enhanced. Previously, it was reported that oxaliplatin, a component of the FOLFOX standard regiment, and bortezomib synergistically activated the JNK-Bcl-xl pathway to induce cell apoptosis in HCT116 cells. Our results demonstrate that leucovorin and bortezomib achieve similar results in both HCT116 cells and xenografts.

Results for the sole trial using bortezomib as a single agent to treat metastatic CRC have been reported. Yet no objective treatment response was observed. One limitation of this trial is that the p53 gene status was not determined, and p53 expression levels were unchanged in the 9 patients in whom it was analyzed. Our study here provides insights into the role of p53 and its transactivational targets in CRC cells treated with bortezomib plus leucovorin. We found that p53 activation as judged by its phosphorylation status is induced
in HCT116 cells, which possess a wild-type \( p53 \) gene\(^{14} \), but not in HT29 cells, which have a mutant \( p53 \) gene\(^{18} \). However, the combination treatment increased the expression of p21, the Bcl-2 family protein PUMA, and the pro-apoptotic Bcl-2 family protein Bax, all of which are \( p53 \) transactivational targets. The up-regulation of PUMA and p21 was confirmed in CRC xenografts mouse models. This result suggests that bortezomib and leucovorin together can activate the \( p53 \) downstream signaling pathway even when the \( p53 \) gene in the CRC cells is mutated.

We further demonstrated that bortezomib and leucovorin effectively induce apoptosis and suppress the growth of CRC xenografts in immunodeficient mice, indicating that the \( \textit{in vitro} \) synergetic action of bortezomib and leucovorin in CRC cells also is achieved \( \textit{in vivo} \). Our data call for a new clinical trial to evaluate bortezomib and leucovorin combinatorial treatment against metastatic CRC. In addition, the mechanism underlying how bortezomib and leucovorin induce the DNA damage response should be investigated.

**Figure 5.** Bortezomib and leucovorin attenuate tumorigenesis of CRC xenografts in mice. HCT116 cells (5 x 10⁵ per mouse) were subcutaneously injected into the right flank of NSG mice. When the tumors reached 200 mm³, mice (n = 5 per group) were arbitrarily assigned to one of four groups for treatment with vehicle, 0.5 mg/kg bortezomib, 80 mg/kg leucovorin, or the combination twice a week by intraperitoneal injection. (A) Gross tumors at day 16 post treatment. (B) Tumor volumes during treatment were measured using a caliper. Data are presented as the mean tumor volume with SEM. (C) Tumor weights at day 16. (D) Western blot analyses of caspases and their activation (n = 3 representative tumors of 5). (E) TUNEL staining to detect apoptosis of tumor cells. A representative image is shown for each group. Arrows points to apoptotic cells. Scale bar = 20 µm. (F) Percentage of TUNEL-positive tumor cells per microscopic field. A total of 10 fields was counted for each group. The percentage was calculated as number of cellular nuclei staining positive divided by the total number of nuclei.
Materials and Methods

Cell lines. Human CRC cell lines HCT116 and HT29 were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum (Gibco, NY, USA). Mycoplasma testing was conducted every 3 months to ensure no contamination. All cells were maintained in a humidified incubator at 37 °C and 5% CO₂. For all studies, CRC cells were grown to ~70% confluence on 10-cm plates and then treated with bortezomib and/or leucovorin calcium for the indicated time periods. All methods related to human cells were carried out in accordance with National Institutes of Health (NIH) guidelines and regulations and Cleveland Clinic Institutional Biosafety Committee polices.

Reagents. Bortezomib was obtained from Selleck Chemical LLC, Houston, TX; leucovorin calcium was from Sigma-Aldrich, St. Louis, MO. The 119 screened compounds (10 mM in DMSO) are from the Approved Oncology Drugs Set VI at the Developmental Therapeutics Program of the National Cancer Institute. Bortezomib is dissolved in ethanol (200 mg/mL) and leucovorin 40 mg/mL in water before diluted with PBS to treat cells or mice.

Compounds screening. CRC HCT116 cells were seeded in duplicate in 96-well plates treated with a final concentration of 0.5 μM with or without leucovorin (10 μM) by the MTT assay (ATCC, Manassas, VA). The time-course and dose-response studies of leucovorin in combination with each of the selected 13 compounds in HCT116 and HT29 CRC cells and assessed viability using the Cell Titer-Glo assay (Promega, Madison, Wisconsin).

Cell viability assay. CRC cells were seeded in triplicate in 96-well plates and treated with bortezomib (0, 3, 10, 30, 100 and 300 nM) and/or leucovorin (10 μM) for 24 or 48 h. Viability was measured using the MTT Cell Proliferation Assay Kit (ATCC, Manassas, VA). Further studies were carried out using the Promega Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, Wisconsin). Cells were then treated with CellTiter-Glo reagent for 10 minutes at room temperature. Luminescence was determined using a multi-mode plate reader (BioTek).

Annexin V/propidium iodide assay. CRC cells were incubated with bortezomib (3 or 10 nM) and/or leucovorin (10 μM) for 12 or 24 h. After the incubation, floating and adherent cells were trypsinized, harvested, and washed with serum-free medium, suspended in binding buffer. The cell suspension was stained with FITC-conjugated annexin V and propidium iodide (PI) using the Alexa Fluor 488 annexin V/Dead Cell Annexin V/propidium iodide assay. CRC cells were incubated with bortezomib (3 or 10 nM) and/or leucovorin (10 μM) for 12 or 24 h. After the incubation, floating and adherent cells were trypsinized, harvested, and washed with serum-free medium, suspended in binding buffer. The cell suspension was stained with FITC-conjugated annexin V and propidium iodide (PI) using the Alexa Fluor 488 annexin V/Dead Cell Annexin V/propidium iodide assay. CRC cells were incubated with bortezomib (3 or 10 nM) and/or leucovorin (10 μM) for 12 or 24 h. After the incubation, floating and adherent cells were trypsinized, harvested, and washed with serum-free medium, suspended in binding buffer. The cell suspension was stained with FITC-conjugated annexin V and propidium iodide (PI) using the Alexa Fluor 488 annexin V/Dead Cell Annexin V/propidium iodide assay. CRC cells were incubated with bortezomib (3 or 10 nM) and/or leucovorin (10 μM) for 12 or 24 h. After the incubation, floating and adherent cells were trypsinized, harvested, and washed with serum-free medium, suspended in binding buffer. The cell suspension was stained with FITC-conjugated annexin V and propidium iodide (PI) using the Alexa Fluor 488 annexin V/Dead Cell Annexin V/propidium iodide assay. CRC cells were incubated with bortezomib (3 or 10 nM) and/or leucovorin (10 μM) for 12 or 24 h. After the incubation, floating and adherent cells were trypsinized, harvested, and washed with serum-free medium, suspended in binding buffer. The cell suspension was stained with FITC-conjugated annexin V and propidium iodide (PI) using the Alexa Fluor 488 annexin V/Dead Cell Annexin V/propidium iodide assay. CRC cells were incubated with bortezomib (3 or 10 nM) and/or leucovorin (10 μM) for 12 or 24 h. After the incubation, floating and adherent cells were trypsinized, harvested, and washed with serum-free medium, suspended in binding buffer. The cell suspension was stained with FITC-conjugated annexin V and propidium iodide (PI) using the Alexa Fluor 488 annexin V/Dead Cell Annexin V/propidium iodide assay.

Protein extracts and Western blotting analysis. Plates were scraped with 1× Laemmli lysis buffer (including 2.4 M glycerol, 0.14 M Tris (pH 6.8), 0.21 M SDS, and 0.3 mM bromophenol blue), and the collected cells were boiled for 5 min at 95 °C. Protein concentration was measured with BCA protein assay reagent (Pierce, Rockford, IL, USA). The samples were diluted with 1× lysis buffer containing 20 mM dithiothreitol, and equal amounts of protein were loaded on 10–15% SDS-polyacrylamide gels(Mini-PROTEAN TGX Precast gels, Bio-Rad, Hercules, California, separated, and transferred onto PVDF membranes. The membrane was blocked with 5% nonfat dry milk in TBS-Tween-20 (0.1%, v/v) for 1 hour and incubated with primary antibody at 4°C overnight. Horseradish peroxidase–conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized with the Pierce ECL Western blotting substrate (Thermo Scientific, Rockford, IL), according to the provided protocol. Quantitation of X-ray film was carried out by scanning densitometry using area integration. The antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA): caspase-3 (#9662), caspase-8 (#9746), caspase-9 (#9508), cleaved-caspase-3 (#9664), cleaved-caspase-8 (#9496), cleaved-caspase-9 (#9501), PARP (#9542), BCL-2 (#2827), p53 (#2521), p-p53 (Ser46) (#2524), H2AX (#2595), phospho-H2AX (Ser139) (#2577), PUMA (#7467), Bax (#5023), p21 (#2947), phospho-c-Jun (NH2-terminal kinase (JNK) (#9251), p-ERK1/2 (Thr202/Tyr204) (#9101), p-Akt (Ser473) (#4062), and β-actin (#3700). Phosphorylated Bcl-xL (S62) antibody was obtained from Millipore (Billerica, MA, USA).

Animal model. Human colorectal HCT116 xenograft tumors were established by subcutaneously injecting 5 × 10⁶ cells suspended in PBS and Matrigel (Corning, NY, USA) into the right flank of 6-week-old female NSG mice (Jackson, MA, USA). Tumors were measured twice per week when tumor volumes reached ~200 mm³. Mice were randomized into four treatment groups (n = 8 per group). For the drug combination, leucovorin was administered 1 h earlier than bortezomib. PBS was used as the vehicle control. Mice were fed ad libitum and maintained in environments with a controlled temperature of ~22 °C and 12 hour light and dark cycles. After 16 days treatment, animal were sacrificed and tumors were collected. Tissue sections in the vehicle group were stained and served as negative controls. DNA fragmentation by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), according to the provided protocol. Quantitation of X-ray film was carried out by scanning densitometry using area integration. The antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA): caspase-3 (#9662), caspase-8 (#9746), caspase-9 (#9508), cleaved-caspase-3 (#9664), cleaved-caspase-8 (#9496), cleaved-caspase-9 (#9501), PARP (#9542), BCL-2 (#2827), p53 (#2521), p-p53 (Ser46) (#2524), H2AX (#2595), phospho-H2AX (Ser139) (#2577), PUMA (#7467), Bax (#5023), p21 (#2947), phospho-c-Jun (NH2-terminal kinase (JNK) (#9251), p-ERK1/2 (Thr202/Tyr204) (#9101), p-Akt (Ser473) (#4062), and β-actin (#3700). Phosphorylated Bcl-xL (S62) antibody was obtained from Millipore (Billerica, MA, USA).

TUNEL assay. An in situ cell apoptosis detection kit (Trevigen, Gaithersburg, MD, USA) was used to detect DNA fragmentation by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), according to the manufacturer’s instructions. Tissue sections in the vehicle group were stained and served as negative controls. Briefly, sections of paraffin-embedded tissues were deparaffinized, then washed with TBS buffer and permeabilized with proteinase K. DNA strand breaks were then end-labeled with terminal transferase, and the labeled DNA was visualized by fluorescence microscopy.
Statistical analysis. The significance between the vehicle controls versus treatment groups was determined by one-way analysis of variance (ANOVA) with the appropriate post hoc testing using the Tukey’s Test. Statistical analysis was carried out using GraphPad InStat 3 software (GraphPad Software, Inc., San Diego, CA, USA). P < 0.05 was considered statistically significant. Synergism of bortezomib and leucovorin was analyzed with isobologram analysis and combination index (CI) calculation using CompuSyn software (CompuSyn, Inc.). CI values below 1 suggest synergy, whereas CI values above 1 indicate antagonism.

References
1. Haggar, F. A. & Boushey, R. P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22, 191–197 (2009).
2. Marshall, J. L., et al. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrinostest Cancer Res 1, 146–154 (2007).
3. Hagan, S., Orr, M. C. & Doyle, B. Targeted therapies in colorectal cancer—an integrative view by PPM, EPM4 J 4, 3 (2013).
4. Tournigand, C., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22, 229–237 (2004).
5. Tsavdaridis, D., et al. Weekly oxaliplatin (OXA), 5-fluorouracil (FU) and leucovorin (LV) as first line treatment for advanced colorectal cancer (CRC) - A phase II study. J Clin Oncol 22, 3712 (2004).
6. Douillard, J. Y., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (London, England) 355, 1041–1047 (2000).
7. Oliver Metzig, M. et al. Inhibition of caspasases primes colon cancer cells for 5-fluorouracil-induced TNF-alpha-dependent necroptosis driven by RIP1 kinase and NF-kappaB. Oncogene 35, 3399–3409 (2016).
8. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nature reviews. Cancer 3, 330–338 (2003).
9. Tafallin, H., Wettergren, Y., Odin, E. & Derwinger, K. Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages. Cancer Chemother Pharmacol 74, 1167–1174 (2014).
10. Priest, D. G., Schmitz, J. C., Bunni, M. A. & Stuart, R. K. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. Journal of the National Cancer Institute 83, 1806–1812 (1991).
11. Chou, T. C. Drug combination studies and their synergy quantification using the Chou- Talalay method. Cancer research 70, 440–446 (2010).
12. Hong, Y. S. et al. Bortezomib induces G2-M arrest in human colon cancer through ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol 41, 76–82 (2012).
13. Pardott, R. & Garel, A. L. Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am J Pathol 178, 355–360 (2011).
14. Kaeber, M. D., Pebernard, S. & Iggo, R. D. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 279, 7598–7605 (2004).
15. Mah, L. J., El-Osta, A. & Karagiannis, T. C. [gamma]H2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24, 679–686 (2010).
16. Bauer, S. et al. Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells. Cancer Res 70, 150–159 (2010).
17. Lion, M. et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 7, 2866–2875 (2008).
18. Muller, P. A. & Vossden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304–317 (2014).
19. Lopes, U. G., Erhardt, P., Yao, R. & Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272, 12893–12896 (1997).
20. Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Curr Cancer Drug Targets 7, 467–487 (2007).
21. Jagannath, S. et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129, 776–783 (2005).
22. Fujita, T. et al. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anti-cancer drugs 18, 677–686 (2007).
23. Mackay, H. et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11, 5526–5533 (2005).
24. Kozuch, P. S. et al. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol 26, 2320–2326 (2008).
25. Awada, A. et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase II/III dose-escalation study. Br J Cancer 98, 1500–1507 (2008).
26. Cardoso, F. et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 5, 3042–3051 (2006).
27. Codony-Servat, J. et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5, 665–675 (2006).
28. Yang, C. H. et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17, 813–817 (2006).
29. Dreicer, R., Petrlyak, D., Aguas, D., Webb, I. & Roth, B. Phase II/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13, 1208–1215 (2007).
30. Morris, M. J., et al. A phase II trial of bortezomib and prednimus for castration resistant metastatic prostate cancer. J Urol 178, 2378–2383 (2007). discussion 2383–2374.
31. Fanucchi, M. P. et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24, 5025–5033 (2006).
32. Li, T. et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68, 89–93 (2010).
33. Reddy, K. G. Activity of bortezomib in advanced non-small-cell lung cancer. Clin Lung Cancer 6, 141–142 (2004).
39. Kim, S. Y., Song, X., Zhang, L., Bartlett, D. L. & Lee, Y. J. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochem Pharmacol 88, 178–188 (2014).
40. Song, X. et al. Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53. Mol Cancer Res 13, 1533–1543 (2015).
41. Bavi, P. et al. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol 178, 2109–2120 (2011).
42. Uddin, S. et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer research 68, 3379–3388 (2008).
43. Min, H. et al. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells. Cancer Chemother Pharmacol 74, 167–176 (2014).
44. Voutsadakis, I. A. et al. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. International journal of colorectal disease 25, 795–804 (2010).
45. Krekowski, R., Stypulkowska, A. & Cechowska-Pasko, M. Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Molecular and cellular biochemistry 398, 165–173 (2015).
46. Schober, C. et al. Cardiotoxicity of 5-fluorouracil in combination with folic acid in patients with gastrointestinal cancer. Cancer 72, 2242–2247 (1993).
47. Doroshov, I. H. et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8, 491–501 (1990).
48. Naccarati, A. et al. Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer. Mutagenesis 27, 211–218 (2012).

Acknowledgements
The authors are grateful to Dr. Cassandra Talerico for proofreading the manuscript and providing critical comments. This study is supported by NIH R01 (CA177810).

Author Contributions
S.W., L.W., Z.Z., L. Liu. and Y.L. designed the research and performed experiments data. All authors analyzed data. S.W., L. Liu., and Y.L. wrote the manuscript, and all authors approved the final version of the manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017